Form 4: LeMaitre Vascular CEO George W. LeMaitre Reports Stock Sales and PSU Vesting

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, reported multiple transactions involving the company's common stock, including sales and the vesting of Performance Share Units (PSUs).

Summary

• George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On February 29, 2024, LeMaitre sold 1,300 shares at a weighted average price of $68.37, 20,575 shares at $69.69, and 5,984 shares at $70.14.
• Also on February 29, 2024, LeMaitre acquired 5,828 shares upon settlement of a Performance Share Unit (PSU) award granted on December 12, 2022.
• Additionally, 14 shares were acquired upon release of dividend equivalent rights.
• The issuer withheld 432 shares to satisfy tax obligations related to the vesting of the PSUs.
• On March 1, 2024, LeMaitre sold 15,869 shares at a weighted average price of $67.51, 20,200 shares at $68.04, and 950 shares at $69.64.
• On March 4, 2024, LeMaitre sold 32,800 shares at a weighted average price of $67.95 and 3,800 shares at $68.68.
• Following these transactions, LeMaitre directly owns 2,187,526 shares of LeMaitre Vascular stock.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing primarily reports transactions. The sales could be seen as slightly negative, but the PSU vesting is a positive sign. Overall, it's a routine disclosure.

Positives

• The vesting of Performance Share Units indicates that performance targets were met, which is a positive signal.

Negatives

• The CEO's sales of a significant number of shares could be interpreted negatively by the market, potentially signaling a lack of confidence in the company's short-term prospects.

Risks

• Large sales by insiders can create downward pressure on the stock price.
• The market may react negatively to the CEO selling shares, regardless of the underlying reason.

Industry Context

Insider transactions are closely watched in the medical device industry as indicators of management's confidence in the company's future performance. Sales can be driven by various factors, including personal financial planning, and don't always reflect a negative outlook.

Comparison to Industry Standards

• Comparing LeMaitre's insider trading activity to companies like Medtronic (MDT), Boston Scientific (BSX), or Edwards Lifesciences (EW) would require analyzing their respective Form 4 filings over a similar period.
• Generally, consistent and large-scale selling by top executives is viewed more negatively than occasional sales for diversification or personal reasons.
• The vesting of PSUs is a common practice, and the subsequent sale of shares received is also typical, especially for executives with significant equity holdings.

Stakeholder Impact

• Shareholders may react to the reported stock sales, potentially leading to short-term price volatility.
• Employees may be affected by the perceived sentiment surrounding the company's stock performance.

Key Dates